Adimab LLC:企業のM&A・提携動向(医療分野)

GlobalDataが発行した調査報告書(GDPH138084D)
◆英語タイトル:Adimab LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:GDPH138084D
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年1月25日
◆ページ数:42
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥56,500見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥84,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Adimab LLC (Adimab) is a biotechnology company that provides antibody discovery and optimization platform. The company discovers antibodies for a range of disease areas, which include oncology, immunomodulation, inflammation, neuroscience and pain, cardiovascular and metabolic disease, and infectious disease. Its platform delivers and optimizes various panels of therapeutically relevant antibodies that meet the standards for affinity, epitope coverage, species cross-reactivity and developability. The company has completed discovery programs in various protein classes such as serum proteins, TNF superfamily receptors, ECM adhesion receptors, enzymes, natural peptides, cytokines, ion channels and GPCRs. Adimab is headquartered in Lebanon, New Hampshire, the US.

Adimab LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Adimab LLC, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Adimab Raises US$13.8 Million In Series F Financing 12
Partnerships 13
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 13
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 14
iTeos Therapeutics Enters into Agreement with Adimab 15
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 15
Adimab Enters into Research Agreement with Kite Pharma 16
Adimab Enters into Discovery Agreement with Celgene 17
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 18
GlaxoSmithKline Expands its Partnership with Adimab 19
Adimab Enters into Agreement with Acceleron Pharma 20
Adimab Enters into Agreement with Oncothyreon 20
Adimab Enters into Agreement with Surface Oncology 21
Adimab Enters into Agreement with Potenza Therapeutics 22
Five Prime Therapeutics Enters Into Research Agreement With Adimab 23
Jounce Therapeutics Enters Into Research Agreement With Adimab 23
Alector Enters Into Research Agreement With Adimab 24
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 25
Adimab Expands Agreement with Innovent Biologics 26
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 27
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 28
Adimab Enters Into Agreement With Mersana Therapeutics 29
Adimab Enters Into Co-Development Agreement With Gilead Sciences 30
Adimab Enters Into Co-Development Agreement With Biogen Idec 31
Adimab Enters Into Co-Development Agreement With Novo Nordisk 31
Licensing Agreements 32
Kite Pharma Exercises Option for Licensing Agreement with Adimab 32
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 33
Adimab Enters into Licensing Agreement with Merck 34
Adimab Enters Into Licensing Agreement With Novo Nordisk 35
Biogen Idec Enters Into Licensing Agreement With Adimab 36
GlaxoSmithKline Enters Into Licensing Agreement With Adimab 37
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 38
Adimab LLC – Key Competitors 39
Key Employees 40
Locations And Subsidiaries 41
Head Office 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Adimab LLC, Pharmaceuticals & Healthcare, Key Facts 1
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Adimab LLC, Deals By Therapy Area, 2011 to YTD 2017 9
Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Adimab Raises US$13.8 Million In Series F Financing 12
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 13
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 14
iTeos Therapeutics Enters into Agreement with Adimab 15
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 15
Adimab Enters into Research Agreement with Kite Pharma 16
Adimab Enters into Discovery Agreement with Celgene 17
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 18
GlaxoSmithKline Expands its Partnership with Adimab 19
Adimab Enters into Agreement with Acceleron Pharma 20
Adimab Enters into Agreement with Oncothyreon 20
Adimab Enters into Agreement with Surface Oncology 21
Adimab Enters into Agreement with Potenza Therapeutics 22
Five Prime Therapeutics Enters Into Research Agreement With Adimab 23
Jounce Therapeutics Enters Into Research Agreement With Adimab 23
Alector Enters Into Research Agreement With Adimab 24
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 25
Adimab Expands Agreement with Innovent Biologics 26
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 27
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 28
Adimab Enters Into Agreement With Mersana Therapeutics 29
Adimab Enters Into Co-Development Agreement With Gilead Sciences 30
Adimab Enters Into Co-Development Agreement With Biogen Idec 31
Adimab Enters Into Co-Development Agreement With Novo Nordisk 31
Kite Pharma Exercises Option for Licensing Agreement with Adimab 32
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 33
Adimab Enters into Licensing Agreement with Merck 34
Adimab Enters Into Licensing Agreement With Novo Nordisk 35
Biogen Idec Enters Into Licensing Agreement With Adimab 36
GlaxoSmithKline Enters Into Licensing Agreement With Adimab 37
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 38
Adimab LLC, Key Competitors 39
Adimab LLC, Key Employees 40

List of Figures
Adimab LLC, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Adimab LLC, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Adimab LLC:企業のM&A・提携動向(医療分野)(Adimab LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆